IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1101-1125 out of 1232.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

Public Release: 11-Nov-2013
Annals of Family Medicine
November/December 2013 Annals of Family Medicine tip sheet
This tip sheet offers synopses of original research and commentary featured in the November/December 2013 issue of Annals of Family Medicine.

Contact: Angela Sharma
asharma@aafp.org
913-269-2269
American Academy of Family Physicians

Public Release: 11-Nov-2013
Cancer
Young breast cancer patients with poorer financial status may experience delays in seeking care
Researchers who sought to determine why breast cancers are more deadly in young women found that only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, but delays in seeking care are more common in women with fewer financial resources. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Contact: Amy Molnar
sciencenewsroom@wiley.com
201-748-8844
Wiley

Public Release: 8-Nov-2013
Journal of Clinical Investigation
CNIO scientists decipher how the immune system induces liver damage during hepatitis
A study published today in the online edition of The Journal of Clinical Investigation, and carried out by Erwin Wagner's team, Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme, shows how the immune system 'attacks' liver cells during hepatitis by using the AP-1 gene JunB.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 8-Nov-2013
Journal of Clinical Investigation
Researchers identify a histone demethylase associated with non-small cell lung cancer
In this issue of the Journal of Clinical Investigation, MinGyu Lee and colleagues at MD Anderson Cancer Center evaluated histone methylation modifications in NSCLS cell lines and determined that the histone demethylase KDM2A was upregulated in NSCLC cell lines.
National Institutes of Health, Center for Cancer Epigenetics at the UT MD Anderson Cancer Center

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 8-Nov-2013
SITC 2013 Annual Meeting and Associated Programs
CTCA doctor featured expert speaker at Society for Immunotherapy of Cancer
Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America® Western Regional Medical Center is presenting new findings during the Society for Immunotherapy of Cancer national meeting.

Contact: Jennifer Vogel
jennifer.vogel@ctca-hope.com
623-207-3241
Cancer Treatment Centers of America

Public Release: 8-Nov-2013
Journal of Clinical Investigation
JCI early table of contents for Nov. 8, 2013
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Nov., 8, 2013, in the JCI: Ion channel inhibition limits injury-induced loss of kidney filtration, Researchers identify a histone demethylase associated with non-small cell lung cancer,Antibodies against low-density lipoprotein receptor–related protein 4 induce myasthenia gravis, Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy, Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma, and more.
National Institutes of Health, Spanish Ministry of Economy, BBVA Foundation, European Research Council, Flight Attendant Medical Research Institute

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 8-Nov-2013
Journal of Biological Chemistry
TGen-led study reveals TWEAK-Fn14 as key drug target
A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.
Ben and Catherine Ivy Foundation, NIH/National Cancer Institute

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 8-Nov-2013
Oncogene
Penn study identifies new trigger for breast cancer metastasis
For years, scientists have observed that tumor cells from certain breast cancer patients with aggressive forms of the disease contained low levels of mitochondrial DNA. But, until recently, no one was able to explain how this characteristic influenced disease progression. Now, University of Pennsylvania researchers have revealed how a reduction in mitochondrial DNA content leads human breast cancer cells to take on aggressive, metastatic properties.
National Institutes of Health, Harriet Ellison Woodward Trust

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 8-Nov-2013
Cancer Cell
A*STAR scientists uncover potential drug target to nip cancer in the bud
Scientists at A*STAR have discovered an enzyme, Wip1 phosphatase, as a potential target to weed out the progression of cancer. Although studies in the past have revealed that this enzyme plays a critical role in regulating the budding of tumours, scientists have for the first time unearthed a mechanism for its mode of action.
A*STAR

Contact: Vithya Selvam
vithya_selvam@a-star.edu.sg
656-826-6291
Agency for Science, Technology and Research (A*STAR), Singapore

Public Release: 7-Nov-2013
Neuro-Oncology
Common genetic pathway could be conduit to pediatric tumor treatment
Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

Contact: Vanessa Wasta
410-614-2916
Johns Hopkins Medicine

Public Release: 7-Nov-2013
British Journal of Cancer
Tree nut consumption associated with reduced risk of pancreatic cancer in women
In a large prospective study published online in the British Journal of Cancer, researchers looked at the association between nut consumption and risk of pancreatic cancer among 75,680 women in the Nurses' Health Study, with no previous history of cancer. Consumption of nuts, including tree nuts (such as almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts), was inversely associated with risk of pancreatic cancer, independent of other potential risk factors for pancreatic cancer.

Contact: Maureen Ternus, M.S., R.D.
Maureen.ternus@gmail.com
530-574-8865
Motion PR

Public Release: 7-Nov-2013
Cell Reports
UT Southwestern researchers discover a new driver of breast cancer
A team of researchers at UT Southwestern has found that as cholesterol is metabolized, a potent stimulant of breast cancer is created -- one that fuels estrogen-receptor positive breast cancers, and that may also defeat a common treatment strategy for those cancers.

Contact: Alex Lyda
alex.lyda@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 7-Nov-2013
Cell
Breakthrough discoveries on cellular regeneration seek to turn back the body's clock
Two groups of scientists at the Children's Medical Center Research Institute at UT Southwestern have made complementary discoveries that break new ground on efforts to turn back the body's clock on cellular activity, paving the way for a better understanding of stem cells, tissue growth, and regeneration.
National Institutes of Health, Cancer Prevention and Research Institute of Texas

Contact: Lisa Warshaw
lisa.warshaw@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 7-Nov-2013
Cell
Mayo Clinic researchers identify role of Cul4 molecule in genome instability and cancer
Mayo Clinic researchers have shown that a molecule called Cul4 helps to deposit DNA-packaging histone proteins onto DNA, an integral step in cramming yards of genetic code into compact coils that can fit into each cell. When DNA isn't packaged correctly, it can lead to the genomic instability characteristic of many forms of cancer.
National Institutes of Health, Mayo Clinic

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 7-Nov-2013
Biomaterials
Nanoparticles can overcome drug resistance in breast cancer cells
Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast cancer cells, according to a study published in the scientific journal Biomaterials.
Swedish Research Council, Royal Swedish Academy of Sciences, and others

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet

Public Release: 7-Nov-2013
Journal of the American Board of Family Medicine
Female doctors twice as likely to screen low-risk women for cervical cancer with HPV test
How likely is it that your doctor orders the HPV test to screen you for cervical cancer?
National Institutes of Health, NIH/National Cancer Institute

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 7-Nov-2013
Genome Research
HPV can damage genes and chromosomes directly, whole-genome sequencing study shows
A study has identified a new mechanism by which the human papillomavirus (HPV) may contribute to cancer development. Using whole-genome sequencing, researchers show that strains of HPV that cause cervical, head and neck and other cancers can directly damage genes and chromosomes where they insert their DNA into human DNA.
Ohio Cancer Research Association, Oral Cancer Foundation, NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 7-Nov-2013
Nature Biotechnology
Cost-effective method accurately orders DNA sequencing along entire chromosomes
A new computational method has been shown to quickly assign, order and orient DNA sequencing information along entire chromosomes. The method may help overcome a major obstacle that has delayed progress in designing rapid, low-cost -- but still accurate -- ways to assemble genomes from scratch. Data gleaned through this new method can also validate certain types of chromosomal abnormalities in cancer.
National Institutes of Health, NIH/National Human Genome Research Institute, National Science Foundation

Contact: Leila Gray
leilag@uw.edu
206-685-0381
University of Washington

Public Release: 7-Nov-2013
PLOS Genetics
Dartmouth researcher finds novel genetic patterns that make us rethink biology and individuality
Scott Williams, Ph.D., of the iQBS at Dartmouth, has made two novel discoveries: 1) a person can have several DNA mutations in parts of their body, with their original DNA in the rest -- resulting in several different genotypes in one individual -- and 2) some of the same genetic mutations occur in unrelated people. We think of each person's DNA as unique, but if a person can have more than one genotype, this may have broad implications.
National Institutes of Health

Contact: Derik Hertel
derik.hertel@dartmouth.edu
603-650-1203
The Geisel School of Medicine at Dartmouth

Public Release: 7-Nov-2013
Journal of Dairy Science
Peptide derived from cow's milk kills human stomach cancer cells in culture
New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures. The findings, published in the Journal of Dairy Science, provide support for future use of LFcinB25 as a potential therapeutic agent for gastric cancer.

Contact: Eileen Leahy
jdsmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 7-Nov-2013
Molecular Cell
Unique change in protein structure guides production of RNA from DNA
One of biology's most fundamental processes is transcription. It is just one step of many required to build proteins -- and without it life would not exist. However, many aspects of transcription remain shrouded in mystery. But now, scientists at the Gladstone Institutes are shedding light on key aspects of transcription, and in so doing are coming even closer to understanding the importance of this process in the growth and development of cells -- as well as what happens when this process goes awry.
National Institutes of Health, NIH/National Institute of Environmental Health Sciences

Contact: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes

Public Release: 7-Nov-2013
Clinical Gastroenterology and Hepatology
Mayo Clinic: Less-invasive option as effective as esophagus removal in early esophageal cancer
Use of a minimally invasive endoscopic procedure to remove superficial, early stage esophageal cancer is as effective as surgery that takes out and rebuilds the esophagus, according to a study by researchers at Mayo Clinic in Florida.
Mayo Foundation for Medical Education and Research

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic

Public Release: 7-Nov-2013
Proceedings of the National Academy of Sciences
Potential for added medical benefits uncovered for widely used breast cancer drug
Exemestane, a synthetic steroid drug widely prescribed to fight breast cancers that thrive on estrogens, not only inhibits the production of the hormone, but also appears to protect cells throughout the body against damage induced by UV radiation, inflammation and other assaults, according to results of research by Johns Hopkins scientists.
Lewis B. and Dorothy Cullman Foundation, Murakami Noen

Contact: Catherine Kolf
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 7-Nov-2013
Cell
Hope builds for a drug that might shut down a variety of cancers
The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.
National Institutes of Health, Stand Up to Cancer Dream Team Translational Research Grant, Program of the Entertainment Industry

Contact: Sarah Smith
sas2072@med.cornell.edu
646-317-7401
Weill Cornell Medical College

Public Release: 7-Nov-2013
Clinical Cancer Research
Oxygen levels in tumors affect response to treatment
Tumors with lower levels of oxygen -- known as hypoxia -- often respond less well to radiation therapy. There are several agents that can be given to patients before radiotherapy to reduce hypoxia, but these are not given as standard. Being able to measure how well-oxygenated an individual's tumor is would give doctors a valuable way of identifying which patients might benefit from treatment with hypoxia reducing agents before radiotherapy.

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Showing releases 1101-1125 out of 1232.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

  Search News Releases

     

 

 

EurekAlert!